Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Acorda
Pharma
Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda
With sales declining for aging MS drug Fampyra, Biogen has exercised an option to return licensing rights outside of the U.S. to Acorda Therapeutics.
Kevin Dunleavy
Jan 11, 2024 1:15pm
Grünenthal buys up Nebido from Bayer for $500 million
Jul 14, 2022 9:44am
Slow Inbrija launch forces Acorda to slash $800M sales hopes
Feb 13, 2020 10:52am
Acorda's sales team switches gears to promote Inbrija
Jan 15, 2019 11:20am
Acorda pulls off delayed Parkinson’s approval for Inbrija
Dec 26, 2018 2:18pm
Acorda's much-needed Inbrija hits a snag at the FDA
Sep 13, 2018 11:20am
